Cardiovascular disease in dialysis patients

Mario Cozzolino, Michela Mangano, Andrea Stucchi, Paola Ciceri, Ferruccio Conte, Andrea Galassi, Mario Cozzolino, Michela Mangano, Andrea Stucchi, Paola Ciceri, Ferruccio Conte, Andrea Galassi

Abstract

Cardiovascular disease (CVD) is a highly common complication and the first cause of death in patients with end-stage renal disease (ESRD) on haemodialysis (HD). In this population, mortality due to CVD is 20 times higher than in the general population and the majority of maintenance HD patients have CVD. This is likely due to ventricular hypertrophy as well as non-traditional risk factors, such as chronic volume overload, anaemia, inflammation, oxidative stress, chronic kidney disease-mineral bone disorder and other aspects of the 'uraemic milieu'. Better understanding the impact of these numerous factors on CVD would be an important step for prevention and treatment. In this review we focus non-traditional CVD risk factors in HD patients.

Figures

FIGURE 1
FIGURE 1
Cardiovascular disease in dialysis.

References

    1. Fox CS, Matsushita K, Woodward M. et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis of 1 024 977 individuals. Lancet 2012; 380: 1662–1673
    1. Mahmoodi BK, Matsushita K, Woodward M. et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380: 1649–1661
    1. Cozzolino M, Galassi A, Pivari F. et al. The cardiovascular burden in end-stage renal disease. Contrib Nephrol 2017; 191: 44–57
    1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR. et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339–352
    1. Herzog CA, Asinger RW, Berger AK. et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572–586
    1. Moradi H, Sica DA, Kalantar-Zadeh K.. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol 2013; 38: 136–148
    1. Evenepoel P, Meijers BKI, Bammens BRM. et al. Uremic toxins originating from colonic microbial metabolism. Kidney Int 2009; 76: S12–S19
    1. Meijers BK, Bammens B, De Moor B. et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174–1180
    1. Meijers BK, Claes K, Bammens B. et al. P-cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182–1189
    1. Cerini C, Dou L, Anfosso F. et al. P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 2004; 92: 140–150
    1. Ying Y, Yang K, Liu Y. et al. A uremic solute, p-cresol, inhibits the proliferation of endothelial progenitor cells via the p38 pathway. Circ J 2011; 75: 2252–2259
    1. De Smet R, Thermote F, Lameire N. et al. Sevelamer hydrochloride (Renagel) adsorbs the uremic compound indoxyl sulfate, indole and p-cresol. J Am Soc Nephrol 2004; 15: 505A
    1. Niwa T. Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 2010; 72: 1–11
    1. Barisione C, Ghigliotti G, Canepa M. et al. Indoxyl sulfate: a candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease. Curr Drug Targets 2015; 16: 366–372
    1. Shivanna S, Kolandaivelu K, Shashar M. et al. The aryl hydrocarbon receptor is a critical regulator of tissue factor stability and an antithrombotic target in uremia. J Am Soc Nephrol 2016; 27: 189–201
    1. Chitalia VC, Shivanna S, Martorell J. et al. Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation 2013; 127: 365–376
    1. Kamiński TW, Pawlak K, Karbowska M. et al. Indoxyl sulfate—the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrol 2017; 18: 35.
    1. Stinghen AEM, Massy ZA, Vlassara H. et al. Uremic toxicity of advanced glycation end products. J Am Soc Nephrol 2016; 27: 354–370
    1. Haugen E, Nath KA.. The involvement of oxidative stress in the progression of renal injury. Blood Purif 1999; 17: 58–65
    1. Wilcox CS. Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables. Hypertension 2012; 59: 375–381
    1. Ravani P, Tripepi G, Malberti F. et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449–2455
    1. Małyszko J, Matuszkiewicz J.. Rowińska endothelium, asymmetric dimethylarginine, and atherosclerosis in chronic kidney disease. Pol Arch Intern Med 2018; 128: 145–147
    1. Liakopoulos V, Roumeliotis S, Gorny X. et al. Oxidative stress in hemodialysis patients: a review of the literature. Oxid Med Cell Longev 2017; 2017: 1
    1. Chen MF, Chang CL, Liou SY.. Increase in resting levels of superoxide anion in the whole blood of uremic patients on chronic hemodialysis. Blood Purif 1998; 16: 290–300
    1. Nguyen T, Lethias C, Zingraff J. et al. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney International 1985; 28: 158–167
    1. Bayes B, Pastor MC, Bonal J. et al. Homocysteine and lipid peroxidation in haemodialysis: role of folinic acid and vitamin E. Nephrol Dial Transplant 2001; 16: 2172–2175
    1. Morena M, Cristol JP, Bosc JY. et al. Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant 2002; 17: 422–427
    1. Sun J, Axelsson J, Machowska A. et al. Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin J Am Soc Nephrol 2016; 11: 1163–1172
    1. Pedraza-Chaverri J, Sánchez-Lozada LG, Osorio-Alonso H. et al. New pathogenic concepts and therapeutic approaches to oxidative stress in chronic kidney disease. Oxid Med Cell Longev 2016; 2016: 6043601.
    1. Emrich IE, Zawada AM, Martens-Lobenhoffer J. et al. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease. Clin Res Cardiol 2018; 107: 201–213
    1. Lau WL, Waziri ND.. Urea, a true uremic toxin: the empire strikes back. Clin Sci 2016; 131: 3–12
    1. Nesrallah GE, Mustafa RA, MacRae J. et al. Canadian Society of Nephrology guidelines for the management of patients with ESRD treated with intensive hemodialysis. Am J Kidney Dis 2013; 62: 187–198
    1. Vervloet MG, Sezer S, Massy ZA. et al. The role of phosphate in kidney disease. Nat Rev Nephrol 2017; 13: 27–38
    1. Vervloet M, Cozzolino M.. Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int 2017; 91: 808–817
    1. Bover J, Evenepoel P, Ureña-Torres P. et al. Pro: cardiovascular calcifications are clinically relevant. Nephrol Dial Transplant 2015; 30: 345–351
    1. Wang Z, Jiang A, Wei F. et al. Cardiac valve calcification and risk of cardiovascular or all-cause mortality in dialysis patients: a meta-analysis. BMC Cardiovasc Disord 2018; 18: 12.
    1. Ketteler M, Block GA, Evenepoel P. et al. Executive summary of the 2017 KDIGO chronic kidney disease–mineral and bone disorder (CKD–MBD) guideline update: what’s changed and why it matters. Kidney Int 2017; 92: 26–36
    1. Dimkovic N, Schlieper G, Jankovic A. et al. Prognostic value of cardiovascular calcifications in hemodialysis patients: a longitudinal study. Int Urol Nephrol 2018; 50: 939–946
    1. Liabeuf S, Okazaki H, Desjardins L. et al. Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? Nephrol Dial Transplant 2014; 29: 1275–1284
    1. Collado S, Coll E, Nicolau C. et al. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function. BMC Nephrol 2017; 18: 290.
    1. Kuźniewski M, Fedak D, Dumnicka P. et al. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure. Adv Med Sci 2016; 61: 269–275
    1. Pichler G, Haller MC, Kainz A. et al. Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis. Nephrol Dial Transplant 2017; 32: 1566–1578
    1. Huang CL, Moe OW.. Klotho: a novel regulator of calcium and phosphorus homeostasis. Pflugers Arch 2011; 462: 185–193
    1. Desjardins L, Liabeuf S, Renard C. et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012; 23: 2017–2025
    1. Faul C, Amaral AP, Oskouei B. et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393–4408
    1. Cozzolino M, Mazzaferro S.. The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease. Curr Vasc Pharmacol 2010; 8: 404–411
    1. Xie J, Yoon J, An SW. et al. Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 2015; 26: 1150–1160
    1. Hu MC, Shi M, Zhang J. et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010; 78: 1240–1251
    1. Kitagawa M, Sugiyama H, Morinaga H. et al. A decreased level of serum soluble klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One 2013; 8: e56695.
    1. Sircana A, De Michieli F, Parente R. et al. Gut microbiota, hypertension and chronic kidney disease: recent advances. Pharmacol Res 2018: S1043–6618: 31208–31202
    1. Vashistha T, Kalantar-Zadeh K, Molnar MZ. et al. Dialysis modality and correction of uremic metabolic acidosis: relationship with all-cause and cause-specific mortality. Clin J Am Soc Nephrol 2013; 8: 254–264
    1. Raikou VD, Kyriaki D.. Association between low serum bicarbonate concentrations and cardiovascular disease in patients in the end-stage of renal disease. Diseases 2016; 4: 36
    1. Voiculeț C, Zară O, Bogeanu C. et al. The role of oral sodium bicarbonate supplementation in maintaining acid-base balance and its influence on the cardiovascular system in chronic hemodialysis patients - results of a prospective study. J Med Life 2016; 9: 449–454
    1. Pavlovic D. The role of cardiotonic steroids in the pathogenesis of cardiomyopathy in chronic kidney disease. Nephron Clin Pract 2014; 128: 11–21

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe